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Abstract: Chronic platelet disorders (CPD), including chronic immune thrombocytopenic
purpura (cITP), thrombotic thrombocytopenic purpura (TTP) and platelet function disorders
are among the most common bleeding disorders and are associated with morbidity and
mortality. The clinical phenotype and complexity of cITP is much like that of hemophilia.
In cITP and hemophilia, bleeding is problematic for many, complicating employability,
insurability and overall quality-of-life (QoL). While myriad drug therapies are available
for cITP and hemophilia, each are variable in their effectiveness, very few (except for
clotting factor concentrates for hemophilia) alter the natural history of the disorder and
sometimes contribute to specific morbidities and mortality. Like in hemophilia, the manage
ment of cITP is not solely based on access to effective treatment but also includes accurate
diagnosis and comprehensive care by a multidisciplinary team of specialists trained in the
management of bleeding disorders. The model of comprehensive care in Hemophilia
Treatment Centers (HTCs) has been recognized as highly effective, improving life expec
tancy for persons with hemophilia. cITP, and other CPDs, are complex disorders requiring
specialized care. However, an integrated care model with a systematic and reliable popula
tion-based surveillance program does not exist. Extending the Comprehensive Care model
with all its related benefits to the community of persons with cITP is sorely needed. This
review will focus on cITP as a prototype chronic platelet disorder that could benefit greatly
from the Comprehensive Care model.
Keywords: hemophilia, hemorrhage, idiopathic thrombocytopenic purpura, platelet, primary
immune thrombocytopenia, thrombocytopenia
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The analogous history of cITP and hemophilia cannot be overlooked; with similar
advancements in recognition, disease characterization and therapy occurring along
comparable timelines. In the nineteenth century, both hemophilia and ITP were
recognized; ITP was described as morbus maculosus hemorrhagicus and hemophilia
was noted to be a bleeding disorder in males of certain families.1,2 Further advance
ment was made with the use of plasma therapy for hemophilia and splenectomy for
treatment of cITP in the first part of the twentieth century.3,4 In the 1950s–1960s, the
distinction between Hemophilia A and B was made and cITP was determined to be an
autoimmune disorder.5,6 This led to further progress in therapies with cryoprecipitate
used for hemophilia A and corticosteroids as treatment for cITP.7,8 In the 1970s1980s, the discovery of concentrated plasma derived clotting factor allowed for home
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treatment of hemophilia.9 However, this advancement was
dampened by the transmission of human immunodeficiency
virus (HIV), hepatitis C virus (HCV) and hepatitis B virus
(HBV) to persons with hemophilia.10 This led to wide
spread fatalities and subsequent improvement in screening
methods for blood donors and pathogen attenuation steps in
the manufacturing process. During the same era, intrave
nous immunoglobulin (IVIG) was shown to be an effective
treatment for persons with ITP in the 1980s.11 As IVIG is
derived from pooled donor plasma, reports of pathogenic
virus transmission (HCV, HBV) emerged between the mid1980s and the mid-1990s.11 This risk was mitigated with the
introduction of pathogen attenuation steps during the pro
duction of IVIG.11
Advances in the treatment of hemophilia from the last
decade of the twentieth century through the first decade of
the twenty-first century largely refined the quality of clotting
factor concentrates. Recombinant clotting factors emerged in
the mid-1990s and are still considered by many to be the
standard of care for persons with hemophilia.12 Most recently,

non-factor therapies, that either mimic the effect of factor VIII
or “rebalance” the hemostatic defect, have benefited patients,
especially those with neutralizing antibodies (inhibitors) to
clotting factor.13–15 Gene therapy to correct the inherited
defect is the next anticipated treatment advancement.16,17
For cITP, treatment options during the later 1990s, until
the late 2000s remained largely unchanged, except for the
discovery that a hybridized anti-CD20 monoclonal antibody
raised the platelet count in around half of the recipients.18 The
2000s saw affirmation to the longstanding theory that many
patients with cITP not only have accelerated platelet destruc
tion but also impaired platelet production.19 The thrombo
poietin receptor agonists (TPO-RAs) have subsequently
become a vital second-line therapy for adults and children
with cITP.20 Today, targeted immunotherapy is a major focus
of drug development for persons with cITP21 (see Figure 1).

Epidemiology
Hemophilia is almost always caused by hereditary factor VIII
or factor IX deficiency that creates a lifelong bleeding

Figure 1 Historical comparison of hemophilia and cITP.
Abbreviations: cITP, chronic immune thrombocytopenic purpura; IVIG, intravenous immunoglobulin; HIV, human immunodeficiency virus; HBV, hepatitis B virus; HCV,
hepatitis C virus; TPO, thrombopoietin; Syk, spleen tyrosine kinase; mAbs, monoclonal antibodies.
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disorder. Hemophilia affects approximately 400,000 persons
worldwide with more recent estimates suggesting the preva
lence is over 1 million.22,23 In the United States, the preva
lence of hemophilia is estimated to be approximately 20,000,
based on expected births and deaths since 1994.24
Hemophilia A occurs in 1 in 5000 live male births and is
four times as common as hemophilia B.23,24 The overall life
expectancy of persons with hemophilia is now comparable to
that of the general population.25
cITP is an acquired autoimmune disorder that causes
isolated thrombocytopenia and related bleeding. The pre
valence of cITP in the United States is approximately
60,000 persons; nearly three times more prevalent than
hemophilia.26 The diagnosis of cITP is based primarily
on the exclusion of other causes of isolated thrombocyto
penia and there are no clinical or laboratory parameters to
establish its diagnosis.27 The incidence of cITP is difficult
to establish due to limited studies and variable symptomol
ogy, the mildest of which falls short of the threshold for
platelet count testing.28 However, the strongest estimate of
the incidence of acute ITP in children is between 1.9 and
6.4 per 100,000 children/year and in adults, is between 1.6
and 3.9 per 100,000 adults/year.29

Ansteatt et al

Table 1 Comparison of Clinical and Non-Clinical Aspects of
Hemophilia and cITP
Hemophilia

cITP

Age Affected

Beginning at Birth

Any Age

Duration

Lifelong

Typically Lifelong
Once Diagnosed

Main Sites of Bleeding
● Joints

Common

Rare

Mucocutaneous

Common

Common

Gastrointestinal
Genitourinary

Common
Common

Common
Common

CNS

Uncommon

Uncommon

Treatment costs

Very expensive

Very expensive

Health-related

Pain, hemarthrosis,

Fatigue, anxiety,

Quality of Life

anxiety, ADL

depression, ADL

limitations, work/
school absenteeism,

limitations, work/
school absenteeism,

social functioning,

social isolation,

treatment related
burden/concerns36

treatment related
burden/

●
●
●
●

concerns43–45
Advocacy

Shared Clinical Challenges in
Hemophilia and cITP
Hemophilia and cITP are bleeding disorders with
a spectrum of phenotypes and much clinical overlap. The
clinical phenotype of hemophilia is directly related to the
severity of the factor deficiency, but with large variability
in the bleeding phenotype among patients with any sever
ity of hemophilia.30 The clinical manifestations of hemo
philia include spontaneous bleeding as well as delayed
bleeding after trauma. Beginning in infancy, patients may
present with a cephalohematoma, subgaleal or intracereb
ral hemorrhage.31 As they grow into toddlers and then
children, they often present with hemarthrosis, intramus
cular hemorrhage, soft tissue hematomas, hematuria, and,
less commonly, hematemesis, hematochezia and intracra
nial hemorrhage.31 Intracranial hemorrhage (ICH) remains
the main cause of fatal bleeding in persons with
hemophilia.
Bleeding associated with hemophilia and cITP are very
similar, with the exception that persons with cITP rarely
have bleeding in their joints (Table 1). Mucocutaneous,
gastrointestinal and genitourinary bleeding are common,
fortunately CNS hemorrhage is less common, especially in
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International: WFH

National: PDSA

National: NHF, HFA,

Local: Affiliates of

HA
State: National

PDSA

Organization
Chapters
Local: HTCs
Comprehensive Care
Centers

National network of
HTCs

None

Abbreviations: cITP, chronic immune thrombocytopenia purpura; ICH, intracra
nial hemorrhage; CNS, central nervous system; ADL, activities of daily living; WFH,
World Federation of Hemophilia; NHF, National Hemophilia Foundation; HFA,
Hemophilia Federation of America; HA, Hemophilia Alliance; HTCs, Hemophilia
Treatment Centers; PDSA, Platelet Disorder Support Association.

the young.32,33 The severity of thrombocytopenia corre
lates directly with the bleeding risk but not entirely, many
patients with very low platelet counts have only mild
bleeding such as easy bruising.28,34 Comparatively, per
sons with severe bleeding most often have platelet counts
less than 10,000–20,000/µL.35
Like hemophilia, the main cause of fatal bleeding in
patients with ITP is intracranial hemorrhage (ICH), the
incidence of which is 0.1–0.5% in children, 1% in adults
with acute ITP, and 5% in adults with cITP.32 Severe and
life-threatening bleeding affects a subset of persons with
hemophilia and cITP which may alter the lifespan of
persons with either disorder.33 When thrombocytopenia
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related to cITP is left untreated, a 70-year-old woman
loses 5 quality-adjusted life years (QALY), whereas a 25year-old woman will lose approximately 15 QALY of
potential life expectancy.33

Improving Quality of Life for
Persons with cITP
At an early age, persons with hemophilia must learn to
adapt to the essential therapies and the overall complexity
of the disorder. As treatments and therapies continue to
advance, there has been an emphasis on health-related
quality of life (HRQoL) as an outcome measure.36 The
long-term complications of hemophilia have had effects on
HRQoL, revealing that persons with hemophilia experi
ence depression and anxiety more often than the general
population.36 In addition, the presence of one or more
target joints has a major impact on HRQoL for persons
with severe hemophilia.36
Like in hemophilia, it is important to understand how
cITP can impact HRQoL (Table 1). The effects of cITP on
a person’s HRQoL should not be overlooked; including
emotional and functional health, work life, social and
leisure activities, and reproductive health.37 Patients char
acterize the emotional toll by depression, anxiety and
report it affecting their overall mental health. In addition,
fatigue, fear of bleeding, and the need to limit daily activ
ities are pervasive sequalae of cITP.38 cITP during child
hood may negatively impact the HRQoL of the child with
cITP and their parents.38 However, when children receive
platelet-enhancing therapy to maintain a platelet count in
the hemostatic range, HRQoL in children and parental
burden improve.39 Although studies of HRQoL have
helped in our understanding of the clinical and sociologi
cal burden for persons with cITP, more short- and longterm studies are needed to fully appreciate the struggle
experienced by many patients.

The Evolution of Comprehensive
Care for Hemophilia
Comprehensive Care for persons with hemophilia is defined
as the continuous supervision of all medical and psychologi
cal aspects affecting the patient and their family.40 Early
detection, diagnosis, prevention, treatment, along with psy
chosocial and educational support are all factors needed to
provide optimal management for patients with bleeding
disorders.41 Recognized since the 1960s, comprehensive
clinical management of hemophilia and related inherited
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bleeding disorders require a multidisciplinary integrated
approach at specialized establishments called Hemophilia
Treatment Centers (HTCs).42 Over the past 60 years, this
model has been expanded to include patients with other rare
inherited or acquired bleeding disorders such as von
Willebrand disease, Hereditary Hemorrhagic Telangiectasia,
and acquired hemophilias, to name a few.
The approach implemented by Comprehensive Care
clinics includes focused education incorporating the basics
of hemophilia and other bleeding disorders. These include
training about bleeding prevention, managing complica
tions, QoL improvement and self-advocacy.41 In addition,
advocacy organizations exist on the local, state, national,
and international levels; providing education, empowering
individuals, and aiding in financial burdens by actively
pursuing long-term relationships with individuals and
organizations that align with the tenets of Comprehensive
Care.43,44 For patients with hemophilia, HTCs provide
multidisciplinary expertise in bleeding disorders, indivi
dualized management plans, readily available access to
multiple medical disciplines, with a focus on preventative
medicine.45 Collectively, this design optimizes effective
ness and efficiency of health care management.
The model of care in comprehensive HTCs has become
the standard for persons with hemophilia worldwide. It has
improved access to care for many thousands of patients
while providing the opportunity for family involvement
which improves therapy adherence.40 The HTCs have advo
cated progress through basic, translational and clinical
research. In addition, care at HTCs reduces health care
costs, by decreasing emergency room visits, decreasing
absenteeism from work or school and preventing lifealtering sequalae of hemophilia.45 In another CDCsponsored study, HTCs were shown to reduce mortality
among persons with hemophilia by 40% as well as decrease
healthcare resource utilization.45,46 Comprehensive care is
one of the essential principles in the model for the develop
ment of a national healthcare program for patients with
hemophilia.31 HTCs have been established to guarantee
patients and families access to all services essential for the
management of their bleeding disorder.31 Within these com
prehensive HTCs, the core team members typically include
hematologists trained in the management of bleeding dis
orders, nurses, clinical specialists, nurse practitioners,
laboratory staff, physical therapists, medical social workers,
and may include dentists, genetic counselors, dieticians,
clinical research coordinators, psychologists as well as
other specialists that aid in the coordination of care.
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Current standard of care for patients with hemophilia
now provides safe and effective treatment, allowing
growth into the adult life with minimal disability,
a normal lifestyle and employment opportunities.21,45 In
the 1990s, approximately 67% of persons with hemophilia
received care at HTCs at least once a year.45 More
recently, in one US HTC, approximately 81.7% of persons
with hemophilia receive care at least once a year.46 Those
that benefit from care at HTCs have a reduced rate of
emergency department (ED) utilization and an increased
rate of prophylaxis and self-infusion compared to those
receiving care outside of the HTC network.46

Potential Value of Comprehensive
Care for cITP
Despite advances in medical therapy, the long-term mor
bidity and mortality of cITP remains. In the United States,
a limited number of hematologists have focused expertise in
cITP. To improve health outcomes and HRQoL, a network
of medical centers that focuses on the diagnosis, manage
ment and prevention of complications of cITP is needed.
The contributing centers would adopt or extend the
Comprehensive Care model within an existing
Hemophilia Treatment Center. This would include diseasespecific education, outreach and advocacy programs, and
conduct longitudinal surveillance on the complications of
treatment. The Comprehensive Care model utilized in per
sons with hemophilia is well-suited for patients with plate
let disorders. This model already incorporates integrated
care for patients with inherited platelet disorders, including
disorders of platelet number and/or function. This includes
Bernard Soulier syndrome, Glanzmann Thrombasthenia,
MYH9 disorders and Platelet Storage Pool Defect, to
name a few.
The core members of the Comprehensive Care cITP
team should be the same as those in the Comprehensive
Care model for hemophilia: hematologists, nurse practi
tioners, nurses, dentists, laboratory staff, physical thera
pists, medical social workers, and clinical psychologists,
but may include immunologists, dieticians, and clinical
research coordinators. Patients with cITP may be broadly
affected by the disease, specifically the clinical conse
quences of bleeding episodes, fear of bleeding, fatigue,
decreased emotional health, social isolation, and reproduc
tive health issues (see Table 1).37,47
The model of Comprehensive Care in HTCs has been
recognized to improve many aspects of health, including

Journal of Blood Medicine 2020:11
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life expectancy. An expert team would be equally as valu
able to persons with cITP. However, an integrated care
model with a reliable population-based surveillance pro
gram does not exist for cITP. Although advocacy groups,
like Platelet Disorder Support Association (PDSA), have
provided an invaluable resource for persons with cITP for
the past 20 years, integration with the site of clinical care
is usually lacking.48 The PDSA would be a logical
liaison to the ITP treatment centers for patient education
and advocacy, similar to the relationship of the National
Hemophilia Foundation (NHF) to HTCs. Given the simi
larities between cITP and hemophilia and the success of
comprehensive care centers in caring for persons with
hemophilia, the Comprehensive Care model for hemophi
lia should be extended to persons with cITP.
In late 2017, the Bleeding and Clotting Disorders
Institute (BCDI) in Peoria, Illinois launched the first ever
Comprehensive Care Clinic in the US for persons with
cITP. Beyond the Comprehensive Clinic team (hematolo
gist, nurse practitioner, nurse coordinator, physical thera
pist, pharmacist, dentist, and medical social worker), each
cITP patient is also seen by an immunologist and dietician.
The addition of the immunologist has proven to be parti
cularly beneficial and has led to the diagnosis of additional
immunological disorders in some patients, such as com
mon variable immune deficiency (CVID) and various
autoimmune disorders.
The ITP program at BCDI provides care for approxi
mately 200 patients from 16 US states and Mexico. Of
these, more than fifty have been served on at least one
occasion in the Comprehensive Care Clinic. The imple
mentation of comprehensive care transcends the formal
clinic encounter and, in some cases results in more than
200 interactions per year between the patient and various
members of the care team. The response to the
Comprehensive Care Clinic for cITP at BCDI has been
tremendously positive and patients have reported an over
all improvement in ease of their activities of daily living.
Formal studies of clinical, psychosocial and economic out
comes are needed and in process at BCDI.

Conclusions
The complex phenotype of cITP is much like that of
hemophilia, necessitating specialized care. A better under
standing of the natural history of cITP, including its impact
on HRQoL and drug safety in the treatment of cITP is
urgently needed. To accomplish this, the Comprehensive
Care model used for persons with hemophilia should be
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extended to include adults and children with cITP by
adapting the infrastructure used for HTCs in the US to
serve this patient population.
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